Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies

Bergen, 2016, Prognostic impact of breast cancer subtypes in elderly patients, Breast Cancer Res Treat, 157, 91, 10.1007/s10549-016-3787-y Kartal, 2013, Diagnosis, treatment characteristics, and survival of women with breast cancer aged 65 and above: a hospital-based retrospective study, BMC Womens Health, 13, 34, 10.1186/1472-6874-13-34 Biganzoli, 2012, Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA), Lancet Oncol, 13, e148, 10.1016/S1470-2045(11)70383-7 Muss, 2010, Coming of age: breast cancer in seniors, Oncologist, 15, 57, 10.1634/theoncologist.2010-S5-57 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), 2013 Fry, 2004, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts, Mol Cancer Ther, 3, 1427, 10.1158/1535-7163.1427.3.11 Toogood, 2005, Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6, J Med Chem, 48, 2388, 10.1021/jm049354h Finn, 2009, PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro, Breast Cancer Res, 11, R77, 10.1186/bcr2419 Finn, 2015, The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study, Lancet Oncol, 16, 25, 10.1016/S1470-2045(14)71159-3 Cristofanilli, 2016, Lancet Oncol, 17, 425, 10.1016/S1470-2045(15)00613-0 Turner, 2015, Palbociclib in hormone-receptor-positive advanced breast cancer, N Engl J Med, 373, 209, 10.1056/NEJMoa1505270 Finn, 2016, Palbociclib and letrozole in advanced breast cancer, N Engl J Med, 375, 1925, 10.1056/NEJMoa1607303 IBRANCE (palbociclib), 2017 IBRANCE® (palbociclib), 2017 Wildiers, 2007, Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology, Lancet Oncol, 8, 1101, 10.1016/S1470-2045(07)70378-9 Yancik, 2004, Cancer in older persons: an international issue in an aging world, Semin Oncol, 31, 128, 10.1053/j.seminoncol.2003.12.024 Lewis, 2003, Participation of patients 65 years of age or older in cancer clinical trials, J Clin Oncol, 21, 1383, 10.1200/JCO.2003.08.010 Bernardi, 2008, Treatment of breast cancer in older women, Acta Oncol, 47, 187, 10.1080/02841860701630234 Turner NC, André F, Cristofanilli M, et al. Treatment postprogression in women with endocrine-resistant HR+ HER2– advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3. In: 39th Annual San Antonio breast cancer symposium (SABCS) December 6–10, 2016; San Antonio, TX, USA. Balducci, 2003, Myelosuppression and its consequences in elderly patients with cancer, Oncology (Williston Park), 17, 27 Harbeck, 2016, Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial, Ann Oncol, 27, 1047, 10.1093/annonc/mdw139 Van Leeuwen, 2011, The effect of under-treatment of breast cancer in women 80 years of age and older, Crit Rev Oncol Hematol, 79, 315, 10.1016/j.critrevonc.2010.05.010 Malik, 2013, Undertreated breast cancer in the elderly, J Cancer Epidemiol, 2013, 893104, 10.1155/2013/893104 Yancik, 2001, Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older, JAMA, 285, 885, 10.1001/jama.285.7.885 Durairaj, 2018, Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer, Anticancer Drugs, 29, 271, 10.1097/CAD.0000000000000589 Yu, 2017, Physiologically based pharmacokinetic modeling of palbociclib, J Clin Pharmacol, 57, 173, 10.1002/jcph.792